21世纪经济报道记者 唐唯珂 广州报道 医药板块的暖意正从创新药向产业链上下游扩散。 7月28日，药明康德(603259.SH)发布半年报，公司上半年实现营业收入207.99亿元，同比增长20.64%； 归属于上市公司股东的净利润85.61亿元，同比增长101.92%。 药明康德预计2025年持续经营业务收入重回双位数增长，增速从10-15%上调至13-17%。此外，药明康 德预计全年整体收入从人民币415-430亿元上调至人民币425-435亿元，将持续聚焦CRDMO核心业务， 持续提高生产经营效率。 这也让业内对CXO的市场信心倍增，而从市场数据也不难看出，CXO板块正迎来估值恢复。截至2025 年07月28日，港股通医药ETF（159776）上涨2.01%，最新价报1.321元，盘中成交额已达1.18亿元，换 手率94.78%。此前，7月25日医药股延续活跃，CXO概念股震荡走高，博腾股份涨超8%，康龙化成、 昭衍新药、泰格医药等跟涨。 创新药的"卖铲人"CXO（医药研发及生产外包）板块近期成为资金追逐焦点，相关ETF流通份额单月增 长近10亿份。 国家医保局推动高水平科技创新成果尽快进入临床，意味着临 ...

"牛市"相关研报增多 随着近日沪指在时隔9个月后首次突破3600点，"牛市氛围"逐渐成为A股市场的主流叙事，市场预测的 目标点位不断抬升。那么，作为行情风向标，券商研究所最近发布报告、路演、电话会、调研的频次是 不是也"水涨船高"呢? 据慧博智能终端数据，最近一周内，券商总共发布了各类投资策略研报近224份，研报数量较此前没有 明显增多。 时值中报披露静默期，最近券商对上市公司的调研也有所减少。据Choice数据统计，近一个月，券商调 研次数达到3080次，比近6个月的平均值下降较多。 不过值得关注的是，近期券商对于"牛市"的呼声较此前明显增多。据慧博智能终端数据，最近一个月 内，标题出现"牛市"的券商策略报告多达13篇。相比之下，最近三个月内，标题出现"牛市"的券商策略 报告是23篇。也就是说，其中有57%的"牛市"研报发布时间是近一个月内。而一些研报即使标题里没有 出现"牛市"，但看多的情绪溢于言表，比如某头部券商策略团队最新的观点明确"3600不是终点"。 与此同时，近期，各券商举办的路演，"牛市"也成为关键词。据进门财经，7月以来（截至7月28日）， 券商举办的各类以"牛市"（也包括商品牛市）为关键词 ...

Core Viewpoint - The article highlights the significant rise of the humanoid robot sector, particularly driven by the recent World Artificial Intelligence Conference (WAIC2025), which showcased numerous innovative products and applications, indicating a strong potential for commercialization and investment opportunities in this field [9][26]. Group 1: Market Performance - On Monday, the A-share market showed slight fluctuations, with the Shanghai Composite Index rising by 0.12%, the Shenzhen Component Index by 0.44%, and the ChiNext Index by 0.96% [1]. - The stock of Upwind New Materials surged again, marking a cumulative increase of over 10 times this year, making it the first stock in A-shares to achieve a tenfold increase since 2025 [1][19]. Group 2: Humanoid Robot Sector - The humanoid robot sector has gained traction due to various catalysts, including the recent showcase of humanoid robots at WAIC2025, which featured over 60 models demonstrating practical applications [9][12]. - The event attracted significant attention, with over 800 companies participating and showcasing a wide range of AI-related products, indicating a robust ecosystem developing around humanoid robots [9][29]. - The commercialization of humanoid robots is expected to accelerate, with companies like Zhiyuan and Yushun preparing for IPOs, which could further drive investment interest in the sector [17][18]. Group 3: Investment Opportunities - The article suggests that the humanoid robot sector presents substantial investment opportunities, particularly as the industry moves towards commercialization and mass production [25][26]. - The demand for core components of humanoid robots is expected to increase, benefiting domestic companies that achieve technological breakthroughs [30]. - The China Europe Index Fund for robots has shown strong performance, with a year-to-date increase of over 15% and a one-year cumulative increase of over 55%, outperforming the CSI 300 Index by more than 30 percentage points [33][34].

港股三大指数收盘涨跌不一，恒生指数早盘一度冲高超1%，最终收涨0.68%，国企指数涨0.29%，恒生科技指数跌0.24%，市场情绪总体表现平稳。 | 代码 | 名称 | 最新价 | 涨跌额 | 涨跌幅 | | --- | --- | --- | --- | --- | | 800000 | 恒生指数 | ○ 25562.13 | +173.78 | 0.68% | | 800100 | 国企指数 | 9177.15 | +26.66 | 0.29% | | 800700 | 恒生科技指数 | 5664.02 | -13.88 | -0.24% | 盘面上，大型科技股走势分化，大金融股部分表现活跃，内险股涨幅较为明显，中资券商股涨跌不一，其中友邦保险涨近5%，中国太保涨近4%；药品类股 持续上涨行情，创新药概念股方面涨幅亮眼，与GSK达成潜在125亿美元组合授权协议，恒瑞医药大涨24.5%且创上市新高；教育股、濠赌股、电信股、建 材水泥股、手游股多数表现活跃。另一方面，航空股跌幅居前，三大航空股均跌超3%，"反内卷"部分板块下跌明显，光伏股、煤炭股、钢铁股走低，石油 股、汽车股、餐饮股普遍表现弱势。 | Cor ...

Core Viewpoint - The innovative pharmaceutical sector in A-shares has shown significant strength, with Heng Rui Pharmaceutical leading the surge, indicating a positive market sentiment towards the industry [1][5]. Group 1: Heng Rui Pharmaceutical Developments - Heng Rui Pharmaceutical announced a deal with GSK, granting exclusive global rights to the HRS-9821 project and up to 11 additional projects, with an upfront payment of $500 million and potential milestone payments totaling approximately $12 billion [4][5]. - The company has accelerated its internationalization process, with expectations of 2-3 innovative drug authorizations annually, enhancing profit margins through upfront payments and substantial overseas sales revenue [6]. - Since 2018, Heng Rui has engaged in 13 licensing transactions with global partners, involving 16 molecular entities, with a total potential transaction value of around $14 billion and upfront payments totaling approximately $600 million [6]. Group 2: Market Reactions and Trends - The entire innovative pharmaceutical sector has been buoyed by Heng Rui's performance, with significant gains in various pharmaceutical stocks, including a notable increase in the domestic first drug ETF [9]. - Citigroup has raised target prices for several Chinese pharmaceutical companies, highlighting optimism for next-generation immuno-oncology therapies, which are expected to reshape treatment paradigms [4][10]. - The total addressable market for next-generation immunotherapy drugs is projected to exceed $62 billion, with specific companies like Kangfang Biotech and Innovent Biologics showing promising data [10].

Group 1 - A-shares have experienced wide fluctuations since 2025, with the overall trend showing mixed performance across major indices [1] - As of June 23, 2025, the cumulative performance of key A-share indices includes: Shanghai Composite Index up 0.89%, Shenzhen Component down 3.52%, ChiNext down 5.79%, CSI 300 down 1.96%, STAR 50 down 2.78%, and Wind All A Index up 2.17% [1] - The STAR 50 index has seen a continuous decline from March to June, erasing the 12.95% gain from February [1] Group 2 - The new narrative logic of the Chinese market is becoming clearer, with small-cap stocks outperforming large-cap stocks, as evidenced by the CSI 1000 index rising over 10% [3] - New industry sectors such as stablecoins, DeepSeek, pet economy, innovative drugs, and robotics have shown significant activity, with gains exceeding 20% [3] - Financial policies are being strengthened, with structural tools being enhanced, leading to a positive accumulation of fundamental factors for banks [3] Group 3 - Global capital is increasingly focused on the Chinese market, with significant investments from overseas long-term funds, including a $50 million investment by a German pension fund [5] - Over 30 billion yuan has been added to Hong Kong-themed ETFs in the past month, indicating strong interest in the Hong Kong market [5] - Public funds are intensifying their focus on Hong Kong stocks, with many companies launching QDII products targeting this market [5] Group 4 - The short-term trend of the market is strong, with noticeable inflows of incremental capital, although the overall market profitability remains weak [7] - The A-share market has maintained stable trading activity under the management's policy to keep the capital market active [11] - The recent rebound in the Shanghai Composite Index has been primarily driven by financial stocks and resource anti-involution concepts [11]

Group 1 - Allianz Fund announced a change in leadership, with Wu Jiayao resigning as chairman and General Manager Shen Liang taking over the role [1] - Over 100 public funds have added new sales institutions in July, with more than 156 announcements made by over 20 fund management companies [2] - The number of applications for ChiNext-related index funds has surged 3.7 times year-on-year, with 42 funds submitted for registration this year [3] Group 2 - Fund manager Zheng Ning focuses on innovative drug investments, highlighting a fundamental-driven market with significant growth in R&D and favorable policies [4] - Zheng Ning identifies two main types of players in the innovative drug sector: new entrants and traditional pharmaceutical companies undergoing transformation [4] - The innovative drug sector remains strong, with stocks like Heng Rui Pharmaceutical hitting the limit up, and related ETFs showing gains of up to 4.10% [5][6] Group 3 - The market experienced a rebound, with the Shanghai Composite Index rising by 0.12% and the ChiNext Index increasing by 0.96%, while total trading volume decreased by 450 billion yuan [4] - Innovative drug ETFs showed strong performance, with several funds reporting gains around 4% [6][8] - Conversely, the STAR 50 ETF led declines with a drop of 14.01%, while energy and coal ETFs also fell by over 2.5% [7]

Group 1 - The core viewpoint of the article highlights a significant increase in the stock prices of innovative pharmaceutical companies, driven by a major licensing deal announced by Heng Rui Pharmaceutical with GlaxoSmithKline (GSK) worth up to $12.5 billion [1] - Heng Rui Pharmaceutical's stock rose by 17.34% to HKD 79.85, while other companies like Sanofi Pharmaceutical and China Biologic Products also saw notable increases in their stock prices [1] - The global pharmaceutical transaction volume reached 456 deals in the first half of 2025, a 32% year-on-year increase, with total upfront payments soaring to $11.8 billion, a 136% increase compared to the previous year [1] Group 2 - The article mentions that nearly 50% of the total transaction value and over 30% of the transaction volume involved China, indicating the country's significant role in the global pharmaceutical market [1] - There is a favorable policy environment for innovative drug development, with recent government reports and measures supporting the growth of innovative drugs and medical devices [1] - Southwest Securities emphasizes the importance of monitoring investment opportunities in the innovative drug sector, particularly in areas such as business development, research breakthroughs, commercialization, policy implementation, and exceeding performance expectations [1]

Group 1 - The core viewpoint is that the innovative pharmaceutical ETF (560900) has shown significant growth, with a 2.09% increase and active trading volume, indicating strong market interest [1] - The innovative pharmaceutical ETF reached a new high in size at 55.51 million yuan as of July 25, with a notable increase of 3 million shares in the past week, leading the comparable funds [1] - The ETF's tracked index, the CSI Innovative Pharmaceutical Industry Index, consists of up to 50 representative listed companies involved in innovative drug research and development [2] Group 2 - The collaboration between Heng Rui Pharmaceutical and GSK involves a payment of 500 million USD for exclusive rights to the HRS-9821 project and potential milestone payments totaling approximately 12 billion USD [1] - The support from relevant departments for the development of innovative drugs and medical devices is expected to alleviate industry competition pressures, enhancing long-term value recognition in the market [2] - The rise of AI-driven technology is prompting investment opportunities in quality tech companies, as highlighted by Morgan Asset Management's integration of its global technology investment products [2]

Group 1 - Heng Rui Medicine announced a License-out collaboration with GlaxoSmithKline (GSK) with a total potential value of up to $12.5 billion, covering an innovative respiratory drug in clinical stages and up to 11 candidates in non-clinical stages [1] - Following the announcement, Heng Rui Medicine's A-shares hit the daily limit, reaching a four-year high, while H-shares surged over 16%, marking a new high since listing [1] - The innovative drug ETFs saw significant activity, with the A-share innovative drug ETF (515120) rising over 2% and reaching a near two-year high, while the Hong Kong innovative drug ETF (513120) increased nearly 1% [1] Group 2 - Haitong International emphasizes the ongoing focus on innovative drugs and the industry chain, highlighting the high prosperity of innovative drugs and the potential for value re-evaluation in Pharma [2] - The market is expected to experience rotation, with assets at historical low valuations likely to see a new round of valuation increases, alongside opportunities arising from the World AI Conference [2] - The second half of the year should focus on recovery lines, such as the revival of medical device procurement and the recovery of demand in life sciences due to global biotech financing [2] Group 3 - Innovative Drug ETF (515120) closely tracks the CSI Innovative Drug Industry Index, investing in A-share innovative drug industry companies [3] - Hong Kong Innovative Drug ETF (513120) tracks the CSI Hong Kong Innovative Drug Index and supports T+0 trading, enhancing liquidity and capital efficiency [3] - Medical ETF Leader (560260) focuses on leading companies in the medical industry, including medical services, devices, and information technology [3]